Free tool
FAERS Monitor: Spravato
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211243 or its brand name (Spravato, Esketamine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
18,798
Serious
13,122
70% of reports
Hospitalization
3,187
Death reported
736
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dissociation3,903
- sedation2,816
- suicidal ideation1,446
- drug ineffective1,134
- nausea1,006
- depression956
- hypertension917
- product dose omission issue852
- hospitalisation850
- anxiety775
- vomiting764
- dizziness670
- blood pressure increased584
- feeling abnormal521
- off label use448
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 677 |
| 2020 | 1,004 |
| 2021 | 1,249 |
| 2022 | 1,463 |
| 2023 | 2,111 |
| 2024 | 3,262 |
| 2025 | 6,094 |
| 2026 | 2,933 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,361 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dissociationSignal | 3,903 | 1158.5 | 1110.4 | 2,218,028 |
| sedationSignal | 2,816 | 134.7 | 129.9 | 333,771 |
| suicidal ideationSignal | 1,446 | 17.9 | 17.1 | 22,850 |
| hospitalisationSignal | 850 | 6.2 | 5.8 | 3,724 |
| hypertensionSignal | 917 | 4.9 | 4.6 | 2,825 |
| depressionSignal | 956 | 4.7 | 4.4 | 2,815 |
| blood pressure increasedSignal | 584 | 4.3 | 4.0 | 1,473 |
| product dose omission issueSignal | 852 | 3.2 | 3.0 | 1,338 |
| anxietySignal | 775 | 3.1 | 2.8 | 1,079 |
| feeling abnormalSignal | 521 | 2.4 | 2.2 | 444 |
| vomiting | 764 | 1.8 | 1.7 | 287 |
| dizziness | 670 | 1.5 | 1.4 | 115 |
| nausea | 1,006 | 1.4 | 1.3 | 131 |
| drug ineffective | 1,134 | 1.0 | 0.9 | 2 |
| off label use | 448 | 0.6 | 0.5 | 149 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.